Overexpression of Fn14 promotes androgen-independent prostate cancer progression through MMP-9 and correlates with poor treatment outcome

Carcinogenesis

Volumn 32, Issue 11, 2011, Pages 1589-1596

  Huang, Mingguo ^a   Narita, Shintaro ^a   Tsuchiya, Norihiko ^a   Ma, Zhiyong ^a   Numakura, Kazuyuki ^a   Obara, Takashi ^a   Tsuruta, Hiroshi ^a   Saito, Mitsuru ^a   Inoue, Takamitsu ^a   Horikawa, Yohei ^a   Satoh, Shigeru ^a   Habuchi, Tomonori ^a  

^a AKITA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CYTOKINE; GELATINASE B; MESSENGER RNA; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CELL STRAIN LNCAP; CONTROLLED STUDY; DNA TRANSFECTION; FN 14 GENE; GENE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; DISEASE PROGRESSION; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, TUMOR NECROSIS FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SURVIVAL RATE; TUMOR NECROSIS FACTORS;

EID: 80755144050     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr182     Document Type: Article

References (34)

1. Jemal,A. et al. (2008) Cancer statistics, 2008. CA Cancer J. Clin., 58, 71-96.
2. Arnold,J.T. et al. (2002) Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocr. Relat. Cancer, 9, 61-73.
3. Burkly,L.C. et al. (2007) TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. Cytokine, 40, 1-16.
4. Winkles,J.A. et al. (2007) Role of TWEAK and Fn14 in tumor biology. Front Biosci., 12, 2761-2771.
5. Winkles,J.A. (2008) The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat. Rev. Drug Discov., 7, 411-425.
6. Dai,L. et al. (2009) TWEAK promotes ovarian cancer cell metastasis via NF-kappaB pathway activation and VEGF expression. Cancer Lett., 283, 159-167.
7. Tran,N.L. et al. (2003) The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors. Am. J. Pathol., 162, 1313-1321.
8. Tran,N.L. et al. (2005) The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFkappaB pathway activation and BCL-XL/BCL-W expression. J. Biol. Chem., 280, 3483-3492.
9. Narita,S. et al. (2008) Candidate genes involved in enhanced growth of human prostate cancer under high fat feeding identified by microarray analysis. Prostate, 68, 321-335.
10. Gialeli,C. et al. (2011) Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J., 278, 16-27.
11. John,A. et al. (2001) The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol. Oncol. Res., 7, 14-23.
12. Ebihara,N. et al. (2009) Expression and function of fibroblast growth factor-inducible 14 in human corneal myofibroblasts. Exp. Eye Res., 89, 256-262.
13. Li,H. et al. (2009) Tumor necrosis factor-related weak inducer of apoptosis augments matrix metalloproteinase 9 (MMP-9) production in skeletal muscle through the activation of nuclear factor-kappaB-inducing kinase and p38 mitogen-activated protein kinase: a potential role of MMP-9 in myopathy. J. Biol. Chem., 284, 4439-4450.
14. Michaelson,J.S. et al. (2005) Tweak induces mammary epithelial branching morphogenesis. Oncogene, 24, 2613-2624.
15. Narita,S. et al. (2008) GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer. Clin. Cancer Res., 14, 5769-5777.
16. Devlin,H.L. et al. (2008) Impairment of the DNA repair and growth arrest pathways by p53R2 silencing enhances DNA damage-induced apoptosis in a p53-dependent manner in prostate cancer cells. Mol. Cancer Res., 6, 808-818.
17. Mamoune,A. et al. (2003) Calpain-2 as a target for limiting prostate cancer invasion. Cancer Res., 63, 4632-4640.
18. Meighan-Mantha,R.L. et al. (1999) The mitogen-inducible Fn14 gene encodes a type I transmembrane protein that modulates fibroblast adhesion and migration. J. Biol. Chem., 274, 33166-33176.
19. Bossen,C. et al. (2006) Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J. Biol. Chem., 281, 13964-13971.
20. Culp,P.A. et al. (2010) Antibodies to TWEAK receptor inhibit human tumor growth through dual mechanisms. Clin. Cancer. Res., 16, 497-508.
21. Tran,N.L. et al. (2006) Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factor-kappaB and correlate with poor patient outcome. Cancer Res., 66, 9535-9542.
22. Monet,M. et al. (2010) Role of cationic channel TRPV2 in promoting prostate cancer migration and progression to androgen resistance. Cancer Res., 70, 1225-1235.
23. Kawakita,T. et al. (2004) Functional expression of TWEAK in human hepatocellular carcinoma: possible implication in cell proliferation and tumor angiogenesis. Biochem. Biophys. Res. Commun., 318, 726-733.
24. Watts,G.S. et al. (2007) Identification of Fn14/TWEAK receptor as a potential therapeutic target in esophageal adenocarcinoma. Int. J. Cancer, 121, 2132-2139.
25. Trudel,D. et al. (2003) Significance of MMP-2 expression in prostate cancer: an immunohistochemical study. Cancer Res., 63, 8511-8515.
26. Zhang,L. et al. (2004) Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer. Prostate Cancer Prostatic Dis., 7, 327-332.
27. Ross,J.S. et al. (2004) Expression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: correlation of nuclear factorkappa B immunoreactivity with disease recurrence. Clin. Cancer Res., 10, 2466-2472.
28. Sweeney,C. et al. (2004) Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin. Cancer Res., 10, 5501-5507.
29. Rennebeck,G. et al. (2005) Anoikis and survival connections in the tumor microenvironment: is there a role in prostate cancer metastasis? Cancer Res., 65, 11230-11235.
30. Fujiwara,Y. et al. (2011) Nafamostat mesilate can prevent adhesion, invasion and peritoneal dissemination of pancreatic cancer thorough nuclear factor kappa-B inhibition. J. Hepatobiliary Pancreat. Sci, 18, 731-739.
31. Whittemore,A.S. et al. (1995) Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J. Natl Cancer Inst., 87, 652-661.
32. Venkateswaran,V. et al. (2007) Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. J. Natl Cancer Inst., 99, 1793-1800.
33. Mydlo,J.H. et al. (2003) Immune function, mitogenicity, and angiogenic growth factor concentrations in lean and obese rodent sera: implications in obesity-related prostate tumor biology. Prostate Cancer Prostatic Dis., 6, 286-289.
34. Grossmann,M.E. et al. (2001) Androgen receptor signaling in androgenrefractory prostate cancer. J. Natl Cancer Inst., 93, 1687-1697.